Frontage Holdings Corp (1521) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Frontage Holdings Corp HK$1.16, price HK$1.08, upside +7.4%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Frontage Holdings Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range HK$0.5000 – HK$8.50 · fair‑value band HK$0.8600 – HK$1.44 · the HK$1.08 price screens below the HK$1.16 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Frontage Holdings in your weekly email
Every Wednesday you see whether Frontage Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
Show more
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing. Further, the company provides laboratory testing services, such as bioanalysis, biomarkers, genomics, chemistry, manufacturing and controls ("CMC") analytical testing, and central laboratory services. It operates in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was founded in 2001 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Consulting Co., ltd.
Stock analysis
Frontage Holdings Corp (1521) currently trades at HK$1.08, while our model-based Fair Value estimate is HK$1.16, implying the stock looks roughly 6.9% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$0.1900 per share, and 0 of the 24 models we run sit above the HK$1.08 price.
Bear case: the Growth DCF group reads lowest at HK$0.1700, and 24 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.8600 (bear) to HK$1.44 (bull), the price of HK$1.08 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Frontage Holdings Corp reported revenue of $257M in FY2025 versus $184M in FY2021, a compound +8.6%/yr. Reported net income was $6.8M in FY2025, compounding −22.1%/yr from FY2021.
Key figures
Market cap HK$2.2B (≈ $279M) · P/E ratio 32.0 · P/S ratio 0.85 · Net margin 2.6% · Return on equity 2.0% · Return on assets (EBIT) 3.9% · Operating margin 6.8% · Revenue (TTM) $257M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 7%, 1521 screens cheaper than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (HK$0.0400 to HK$0.3700). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$0.8600Fair Value HK$1.16Bull HK$1.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+0.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17% vs 0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 6%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −1.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside+7% · Top 25%
Profitability
Return on equity (TTM)2% · Above median
Return on assets2% · Top 25%
Net margin (TTM)3% · Below median
Operating margin (TTM)7% · Above median
Growth and dividend
Revenue growth3% · Above median
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Frontage Holdings Corp (1521) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$1.16 versus a price of HK$1.08, about +7% upside (fairly valued).
What is the fair value of 1521?
Our model-based fair value for Frontage Holdings Corp is HK$1.16 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$1.08.
What is the quality score of 1521?
Frontage Holdings Corp has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Frontage Holdings Corp (1521)?
Our model-based price target is the fair value of HK$1.16 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario HK$0.8600, optimistic scenario HK$1.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Frontage Holdings Corp stock forecast for 2026?
Our models put fair value at HK$1.16, about +7% upside versus a price of HK$1.08 (fairly valued). Cautious scenario HK$0.8600, optimistic scenario HK$1.44. The calculation is refreshed regularly with new filings.
What is the revenue of Frontage Holdings Corp (1521)?
Frontage Holdings Corp reported trailing-twelve-month revenue of about $257M (latest available figure, as of Sep 24, 2026).
What growth is priced into Frontage Holdings Corp (1521)?
For today's price to be fair in a discounted-cash-flow model, Frontage Holdings Corp would have to grow free cash flow by +0.8 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1521 use?
Our models discount Frontage Holdings Corp at 11.8 %: a base by market capitalisation (micro), damped by beta 0.15, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Frontage Holdings Corp that is +0.8 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Frontage Holdings Corp (1521) delivered so far?
Over the past 5 years revenue at Frontage Holdings Corp grew +15.3 % a year. The price currently implies +0.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Frontage Holdings Corp (1521) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Frontage Holdings Corp (+0.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Frontage Holdings Corp (1521)?
The free-cash-flow yield on the price is 11.56 %: that much free cash flow Frontage Holdings Corp produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Frontage Holdings Corp (1521)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Frontage Holdings Corp it is HK$1.16 per share (as of Sep 24, 2026), against a price of HK$1.08. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Frontage Holdings Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1521 trades below its calculated fair value: price HK$1.08, fair value HK$1.16, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1521?
No. The price is what the market pays today (HK$1.08); the fair value is what the company's own numbers justify (HK$1.16). For Frontage Holdings Corp the two are HK$0.0800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Frontage Holdings Corp worth?
The market values Frontage Holdings Corp at about HK$2.2B (market capitalisation, as of Sep 24, 2026). Per share that is HK$1.08; our models calculate a fair value of HK$1.16 per share.
What do the bullish and bearish scenarios say about 1521?
Our models span a range for Frontage Holdings Corp: cautious scenario HK$0.8600, base HK$1.16, optimistic HK$1.44 per share (as of Sep 24, 2026, price HK$1.08). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1521?
Frontage Holdings Corp trades at a price-to-earnings ratio of 32.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$1.16 is built from several models across several years. Other multiples: P/B 0.8, P/S 1.1, EV/EBITDA 6.5.
How solid is the balance sheet of Frontage Holdings Corp (1521)?
Balance-sheet figures for Frontage Holdings Corp (as of Sep 24, 2026): return on equity 2.0%, debt of 0.08 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is 1521 from its 52-week high?
Frontage Holdings Corp trades at HK$1.08, about 20% below its 52-week high of HK$1.35 and 54% above the low of HK$0.7000 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.16 is for.
Which stocks are comparable to Frontage Holdings Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Frontage Holdings Corp stock attractive at the current price?
The data as of Sep 24, 2026: price HK$1.08, calculated fair value HK$1.16 (+7%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1521 calculated?
We run Frontage Holdings Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Frontage Holdings Corp currently trades 7 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Frontage Holdings Corp (1521)?
The closing price on Sep 23, 2026 was HK$1.08. Our model-based fair value is HK$1.16, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Frontage Holdings Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Frontage Holdings Corp
How large is the market capitalisation of Frontage Holdings Corp (1521)?
The market capitalisation of Frontage Holdings Corp is HK$2.2B (≈ $279M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Frontage Holdings Corp (1521)?
The price-to-sales ratio of Frontage Holdings Corp is 0.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Frontage Holdings Corp (1521)?
The net margin of Frontage Holdings Corp is 2.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Frontage Holdings Corp (1521)?
The return on equity (ROE) of Frontage Holdings Corp is 2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Frontage Holdings Corp (1521)?
On an EBIT basis the return on assets of Frontage Holdings Corp is 3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Frontage Holdings Corp (1521)?
The operating margin of Frontage Holdings Corp is 6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Frontage Holdings Corp (1521)?
Revenue at Frontage Holdings Corp is growing +2.9% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Frontage Holdings Corp (1521)?
Earnings per share at Frontage Holdings Corp are growing +324% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Frontage Holdings Corp (1521) carry?
The net debt of Frontage Holdings Corp is $90.6M (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Frontage Holdings Corp in the live analysis
One click puts Frontage Holdings Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026